Results 121 to 130 of about 10,498 (275)
Insulin‐Dependence and Survival in Pancreatic Neuroendocrine Tumors: Results From the US‐NTSG Group
Journal of Surgical Oncology, Volume 133, Issue 2, Page 153-160, February 2026.ABSTRACT Introduction PNETs are rare pancreatic malignancies originating from islet cells and exhibit a strong co‐occurrence with Diabetes Mellitus (DM), associated with worse survival outcomes. However, studies have yet to delineate the impact of insulin dependent (IDDM) and non‐insulin dependent (NIDDM) on poor oncological outcomes. Methods Utilizing
Muhammad Bilal Mirza +11 more
wiley +1 more source
Obesity Science &Practice, Volume 12, Issue 1, February 2026.ABSTRACT Background Incretin therapies yield strong metabolic improvements, but whether adding a weight‐management (WM) clinic confers additional benefit beyond pharmacotherapy alone in routine care is unclear. Objective Evaluate whether referral to WM clinic, alongside standard diabetes care, provides additional benefit for adults with type 2 diabetes
Kathleen M. Robinson +5 more
wiley +1 more source
Environmental Microbiology Reports, Volume 18, Issue 1, February 2026.Metatranscriptomic analysis of Centaurea cyanus revealed diverse plant‐associated viral and bacterial sequences in herbicide‐susceptible and ‐resistant biotypes. While novel partitiviruses occurred independently of resistance status, differences in bacterial community composition may suggest a potential role of the plant microbiome in responses to ...
Katarzyna Marcinkowska +2 more
wiley +1 more source
Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim +4 more
wiley +1 more source
Clinical Epidemiology, 2018 John M Dennis,1 Beverley M Shields,2 Angus G Jones,2 Ewan R Pearson,3 Andrew T Hattersley,2 William E Henley1 On behalf of the MASTERMIND consortium 1Health Statistics Group, University of Exeter Medical School, Exeter, UK; 2National Institute for ...
Dennis JM +5 more
doaj
Frontiers in PharmacologyBackgroundGliclazide, a second-generation sulfonylurea derivative still widely used as a second-line treatment for type 2 diabetes mellitus, is well known to be subject to interindividual differences in bioavailability, leading to variations in ...
Maja Đanić +6 more
doaj +1 more source
Diabetic Medicine, Volume 43, Issue 2, February 2026.Abstract Aims This study assesses national trends and, socio‐demographic and clinical factors associated with polypharmacy and potentially in appropriate prescribing among people with type 2 diabetes in Scotland from 2012 to 2022. Methods Retrospective cohort study using nationwide data from the Scottish Care Information – Diabetes database ...
William Berthon +8 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang +5 more
wiley +1 more source